The Kwan Lion Dance Team has been performing in Cleveland area restaurants and rec centers for Lunar New Year for decades.

Penyidik Subdit I Ditreskrimsus Kepolisian Daerah Kepulauan Riau (Polda Kepri) resmi menetapkan dua orang tersangka dalam kasus penyelundupan daging beku ilegal asal Singapura ANTARA News kepri 4 ...

Merck reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But Merck posted a modest 2026 outlook that ...

Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years. The stock MRK ...

Merck is rated Buy after extending Keytruda's patent protection to late-2029, delaying the anticipated patent cliff, and unlocking significant near-term value. The extended exclusivity creates a ...

Merck forecasts 2026 sales below Wall Street estimates Co plans to offer clarity on $70 billion growth opportunities by 2027 Merck anticipates $2.5 billion impact from generic competition, Medicare ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Merck (MRK) shares slid about 3% in premarket trading on Tuesday after the drugmaker issued a full-year 2026 outlook that came in below Wall Street expectations. The Rahway, New Jersey–based company ...

Robert Davis, Merck CEO, joins 'Mad Money' host Jim Cramer to talk quarterly results, global sales growth, recent acquisitions, and more. Got a confidential news tip? We want to hear from you. Sign up ...

Armed with what CEO Robert Davis called the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its post-Keytruda future with what it foresees as a host of major sales ...

Merck recorded higher revenue in its fourth quarter, but expects earnings growth to slow as it ramps up acquisitions. The healthcare company on Tuesday posted a profit of $2.96 billion, or $1.19 a ...

For all its success across a wide range of cancer types, Merck’s PD-1 superstar Keytruda has never been able to crack the code for one of the toughest-to-treat indications in oncology—ovarian cancer.